JP2020512387A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512387A5
JP2020512387A5 JP2019554000A JP2019554000A JP2020512387A5 JP 2020512387 A5 JP2020512387 A5 JP 2020512387A5 JP 2019554000 A JP2019554000 A JP 2019554000A JP 2019554000 A JP2019554000 A JP 2019554000A JP 2020512387 A5 JP2020512387 A5 JP 2020512387A5
Authority
JP
Japan
Prior art keywords
substituted
group
salt
methoxy
halogen atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019554000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512387A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2018/014501 external-priority patent/WO2018182050A1/en
Publication of JP2020512387A publication Critical patent/JP2020512387A/ja
Publication of JP2020512387A5 publication Critical patent/JP2020512387A5/ja
Ceased legal-status Critical Current

Links

JP2019554000A 2017-03-31 2018-03-29 代謝性障害の治療の為の置換シクリル酢酸誘導体 Ceased JP2020512387A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017072813 2017-03-31
JP2017072813 2017-03-31
PCT/JP2018/014501 WO2018182050A1 (en) 2017-03-31 2018-03-29 Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
JP2020512387A JP2020512387A (ja) 2020-04-23
JP2020512387A5 true JP2020512387A5 (https=) 2021-04-30

Family

ID=62116518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019554000A Ceased JP2020512387A (ja) 2017-03-31 2018-03-29 代謝性障害の治療の為の置換シクリル酢酸誘導体

Country Status (10)

Country Link
US (1) US10968231B2 (https=)
EP (1) EP3601260A1 (https=)
JP (1) JP2020512387A (https=)
KR (1) KR20190136049A (https=)
CN (1) CN110678458A (https=)
AR (1) AR111199A1 (https=)
CA (1) CA3058588C (https=)
MX (1) MX2019011782A (https=)
TW (1) TW201841920A (https=)
WO (1) WO2018182050A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018181847A1 (ja) 2017-03-31 2018-10-04 武田薬品工業株式会社 芳香環化合物
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
AU2020283307B2 (en) 2019-05-31 2025-03-06 Hyundai Pharm Co., Ltd. Novel crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
TWI894280B (zh) * 2020-05-26 2025-08-21 南韓商愛思阿爾法數字醫療科技有限公司 用以治療癌症惡病質之系統、用以治療癌症惡病質之運算系統及其操作方法、以及非暫態電腦可讀取媒體
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN112830933A (zh) * 2021-02-04 2021-05-25 康化(上海)新药研发有限公司 一种3,4-二氢-2H-吡喃并[2,3-b]吡啶合成方法
KR102699076B1 (ko) * 2021-04-01 2024-08-27 현대약품 주식회사 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도
JPWO2023106310A1 (https=) * 2021-12-07 2023-06-15

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
AU2003278600A1 (en) 2002-11-01 2004-05-25 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
AU2004309271A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
TW200740435A (en) 2005-08-10 2007-11-01 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
MX2008011615A (es) * 2006-03-14 2008-09-22 Amgen Inc Derivados de acidos carboxilicos biciclicos utiles para tratar trastornos metabolicos.
RS53230B (sr) 2006-06-27 2014-08-29 Takeda Pharmaceutical Company Limited Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
RU2454415C9 (ru) 2006-10-19 2013-02-27 Такеда Фармасьютикал Компани Лимитед Производное индола
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
JP2010517935A (ja) 2007-02-09 2010-05-27 武田薬品工業株式会社 Ppar−ガンマのパーシャルアゴニストとしての縮合環化合物
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素5員複素環化合物
WO2008156757A1 (en) 2007-06-19 2008-12-24 Takeda Pharmaceutical Company Limited Indazole compounds for activating glucokinase
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
WO2009111056A1 (en) * 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
AU2009303475B2 (en) * 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
CA2795513A1 (en) * 2010-04-06 2011-10-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP6121339B2 (ja) 2012-02-13 2017-04-26 武田薬品工業株式会社 芳香環化合物
PL3031799T3 (pl) 2013-08-09 2018-09-28 Takeda Pharmaceutical Company Limited Związek aromatyczny
WO2017027309A1 (en) 2015-08-12 2017-02-16 Janssen Pharmaceutica Nv Gpr40 agonists for the treatment of type ii diabetes
WO2017027310A1 (en) 2015-08-12 2017-02-16 Janssen Pharmaceutica Nv Gpr40 agonists for the treatment of type ii diabetes
WO2017027312A1 (en) 2015-08-12 2017-02-16 Janssen Pharmaceutica Nv Gpr40 agonists for the treatment of type ii diabetes
JP6627397B2 (ja) 2015-10-09 2020-01-08 富士通オプティカルコンポーネンツ株式会社 光モジュール及び光伝送装置
US10676458B2 (en) 2016-03-29 2020-06-09 Merch Sharp & Dohne Corp. Rahway Antidiabetic bicyclic compounds
WO2018081047A1 (en) 2016-10-25 2018-05-03 Janssen Pharmaceutica Nv Cyclohexyl gpr40 agonists for the treatment of type ii diabetes
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
WO2018181847A1 (ja) * 2017-03-31 2018-10-04 武田薬品工業株式会社 芳香環化合物

Similar Documents

Publication Publication Date Title
JP2020512387A5 (https=)
JP5985611B2 (ja) 炎症および免疫関連用途のための化合物
JP2009523146A5 (https=)
JP2008513515A5 (https=)
JP2016535772A5 (https=)
JP2018127459A5 (https=)
JP2016525130A5 (https=)
KR102212981B1 (ko) 4-알키닐이미다졸 유도체 및 그것을 유효 성분으로서 함유하는 의약
JP2005508967A5 (https=)
JP2014507464A5 (https=)
JP2013129675A5 (https=)
JP2017502940A5 (https=)
WO2014114779A1 (en) N-substituted-5-substituted phthalamic acids as sortilin inhibitors
JP2004529161A5 (https=)
JP2011137006A5 (https=)
JP2016525075A5 (https=)
JP2005509003A5 (https=)
JP2008504304A5 (https=)
JP2020515620A5 (https=)
KR20210005668A (ko) Hpk1 억제제, 그의 제조 방법 및 응용
JP2007500719A5 (https=)
JP2010525023A5 (https=)
JP2006522035A5 (https=)
US7393959B2 (en) Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5
JP2017538689A5 (https=)